

A practical guide for providers on helping patients find Symbicort in stock, including real-time tools, alternative strategies, and workflow tips.
As a prescriber, you've likely heard it from multiple patients: "My pharmacy can't get Symbicort." Intermittent supply disruptions with Symbicort (budesonide/formoterol) have persisted into 2026, creating frustration for patients who depend on this ICS/LABA combination for daily asthma or COPD management.
While supply has improved with the entry of generic budesonide/formoterol products, localized shortages still occur — particularly during respiratory season and at high-volume retail pharmacies. This guide offers practical steps you can integrate into your clinical workflow to help patients maintain uninterrupted access to their maintenance inhaler.
As of 2026, the Symbicort supply landscape includes:
The FDA does not currently list Symbicort as a critical shortage, but pharmacy-level availability remains variable by region and retailer.
Understanding the root causes helps you address patient concerns effectively:
Use Medfinder for Providers to check real-time pharmacy inventory at the point of care. By verifying availability before the patient leaves your office, you can direct them to a pharmacy that has the medication in stock — saving them the frustration of being turned away.
Writing prescriptions for "budesonide/formoterol" rather than "Symbicort" gives pharmacies maximum flexibility to dispense whatever product they have in stock — brand or generic. Avoid writing "dispense as written" unless there's a specific clinical reason to require brand-name.
If you know a patient's usual pharmacy has had supply issues, consider sending the prescription to an independent pharmacy or a mail-order option. Independent pharmacies often maintain better stock of specialty medications through direct wholesaler relationships.
For patients with a history of difficulty filling Symbicort, document a therapeutic alternative in their chart so that switching can happen quickly if needed. Reasonable alternatives include:
Pre-authorizing alternatives with the patient's insurance can eliminate delays when a switch becomes necessary.
Availability and affordability are interconnected — patients who can't afford their copay may not fill the prescription even when it's in stock. Proactively share these resources:
When a switch is necessary, selecting the right alternative depends on several factors:
| Medication | Components | Dosing | Approved For | Generic Available |
|---|---|---|---|---|
| Advair Diskus/HFA | Fluticasone/Salmeterol | Twice daily | Asthma, COPD | Yes (Wixela Inhub) |
| Breo Ellipta | Fluticasone Furoate/Vilanterol | Once daily | Asthma (18+), COPD | Emerging |
| Dulera | Mometasone/Formoterol | Twice daily | Asthma (5+) | Emerging |
Dose equivalence should be determined using GINA or GOLD guideline recommendations, as corticosteroid potency varies across products.
Integrating shortage awareness into your daily workflow doesn't have to be burdensome:
Helping patients navigate Symbicort availability issues is an increasingly common part of respiratory care. By checking availability at the point of prescribing, leveraging generic options, maintaining therapeutic backup plans, and connecting patients with cost resources, you can significantly reduce the disruption that supply variability causes.
For the latest on Symbicort supply status, see our provider shortage update. And for patient-facing resources you can share, visit how to find Symbicort in stock.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.